文献速递核素与放射性配体治疗肿瘤 PET/CT

212Pb标记PSMA靶向α疗法ADVC001的临床前评价

Preclinical Evaluation of [212Pb]Pb-ADVC001: A Prostate-Specific Membrane Antigen-Targeted α-Therapy for Prostate Cancer.
PubMed 文献 · J Nucl Med · 2025-11-03

该临床前研究评估了针对前列腺癌的PSMA靶向α疗法[212Pb]Pb-ADVC001的体外和体内特性。ADVC001对PSMA具有纳摩尔级高亲和力,[212Pb]Pb-ADVC001在PSMA表达细胞中显示特异性细胞毒活性。在PC3-PIP和C4-2异种移植模型中,单次或多次给药可延长生存期,且耐受良好。

要点

  • ADVC001对PSMA的半数抑制浓度达纳摩尔级,[212Pb]Pb-ADVC001对PSMA表达细胞有特异性细胞毒活性。
  • 在PC3-PIP模型中,单次0.46 MBq 212Pb-ADVC001生存获益优于20 MBq 177Lu-PSMA-I&T。
  • 在C4-2模型中,单次0.3、0.8、1.1 MBq 212Pb-ADVC001显著延长中位生存期至34、57、62.5天(对照16天)。

核心结论

  • 临床前结果支持[212Pb]Pb-ADVC001作为靶向α疗法用于前列腺癌患者的临床开发。

研究设计与样本

  • 体外实验:PSMA酶学测定和放射配体结合实验评估亲和力,克隆生成、代谢和影像学细胞毒实验评估细胞毒性。
  • 体内实验:PSMA高表达皮下异种移植模型评估药代动力学和生物分布;PSMA不同表达水平的皮下前列腺癌异种移植模型评估单次和多次给药的疗效。

主要发现

  • ADVC001对PSMA的半数抑制浓度为纳摩尔级。
  • [212Pb]Pb-ADVC001对PSMA表达细胞的半数有效浓度为纳摩尔级。
  • 在PC3-PIP模型中,212Pb-ADVC001肿瘤摄取快速且持久,肾脏清除快,正常组织滞留低。
  • 单次0.46 MBq 212Pb-ADVC001的生存获益优于20 MBq 177Lu-PSMA-I&T。
  • 在C4-2模型中,单次0.3、0.8、1.1 MBq 212Pb-ADVC001使中位生存期分别延长至34、57、62.5天,对照组为16天。

关键数值与推荐

  • PC3-PIP模型中,两次0.5 MBq 212Pb-ADVC001较两次15 MBq 177Lu-PSMA-I&T显著延长中位生存期(86天 vs 45.5天,P < 0.05)。
  • 177Lu-PSMA-I&T(15 MBq)治疗后复发再给予212Pb-ADVC001(0.5 MBq)显示生存获益增强(59.5天)。

临床怎么用

  • 临床前数据支持212Pb-ADVC001作为PSMA靶向α疗法进入临床开发,用于前列腺癌治疗。

局限性

  • 本研究为临床前评估,结果需在临床试验中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate-specific membrane antigen (PSMA)-directed radiopharmaceutical therapies continue to improve treatment outcomes in patients with metastatic castration-resistant prostate cancer. Here, we report the in vitro and in vivo characterization of a PSMA-targeted therapy (ADVC001) specifically designed for targeted α-therapy with 212Pb. Methods: The binding affinity to PSMA was determined by PSMA enzymatic assays and by radioligand binding assays using PSMA-high prostate cancer (PC) cells. In vitro cytotoxicity against PC cell lines with high and medium PSMA expression was evaluated using clonogenic, metabolic, and imaging-based cytotoxic assays. Pharmacokinetics and biodistribution were assessed using PSMA-high subcutaneous tumor xenografts. In vivo single-dose and multidose efficacy was assessed in subcutaneous PC xenograft models expressing various levels of PSMA. Results: A high binding affinity to PSMA was observed for ADVC001 with nanomolar inhibitory concentration of 50% values. In cellular assays, [212Pb]Pb-ADVC001 (212Pb-ADVC001 hereafter for simplicity) exhibited specific cytotoxic activity against PSMA-expressing cells with nanomolar effective concentration of 50% values. In vivo biodistribution of 212Pb-ADVC001 in the PC3-PIP xenograft model revealed rapid and persistent tumor uptake, fast renal clearance, and low retention in normal tissues. Single-dose efficacy studies of 212Pb-ADVC001 (0.46 MBq) showed improved survival compared with [177Lu]Lu-PSMA-I&T (177Lu-PSMA-I&T hereafter for simplicity) (20 MBq) treatment. In a multidose experiment, 2 doses of 212Pb-ADVC001 (0.5 MBq) significantly increased median survival (86 d vs. 45.5 d, P < 0.05) compared with 2 doses of 177Lu-PSMA-I&T (15 MBq). Treatment with 212Pb-ADVC001 (0.5 MBq) after initial 177Lu-PSMA-I&T (15 MBq) relapse showed an enhanced survival benefit (59.5 d). In a C4-2 xenograft model with medium-level PSMA expression, single doses of 0.3, 0.8, and 1.1 MBq of 212Pb-ADVC001 significantly extended median survival to 34, 57, and 62.5 d, compared with untreated cohorts (16 d). All treatments were well tolerated. Conclusion: The preclinical results support the clinical development of 212Pb-ADVC001 as a targeted α-therapy for the treatment of patients with PC.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Liu F, Monterosso ME, Boucher D, et al. Preclinical Evaluation of [212Pb]Pb-ADVC001: A Prostate-Specific Membrane Antigen-Targeted α-Therapy for Prostate Cancer. J Nucl Med. 2025. PMID: 40998733. doi:10.2967/jnumed.125.269707

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。